Overview

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide a safety and feasibility basis for future studies addressing the hypothesis that subcutaneous vaccination with dendritic cells loaded with multiple antigenic epitopes expressed by pancreatic tumor in combination with systemic administration of Poly-ICLC (Hiltonol) will induce anti-tumor immunity.

Phase:

Phase 1

Details

Lead Sponsor:

Carolyn Britten

Collaborator:

Oncovir, Inc.

Treatments:

Carboxymethylcellulose Sodium
Poly I-C
Poly ICLC
Vaccines